Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitor (ICI)-associated early cardiac adverse events (CAEs), mostly acute and fulminant myocarditis, have been well characterized and mainly occur during the first 90 days after ICI therapy initiation. ICI-associated late CAEs (occurring after the first 90 days of tre...
Saved in:
| Main Authors: | Charles Dolladille, Joachim Alexandre, Radj Gervais, Stéphane Allouche, Querntin Dupas, Jeannick Madelaine, Anne-Flore Plane, Francois Comoz, Ariel Aron Cohen, Franck Roland Thuny |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000261.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
by: Alessandro Ceschi, et al.
Published: (2024-11-01) -
Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01) -
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
by: Maria Luisa De Perna, et al.
Published: (2025-08-01) -
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
by: Omar Elghawy, MD, et al.
Published: (2025-09-01) -
Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
by: Carrie Ye, et al.
Published: (2024-07-01)